Defunct Company
Total Trials
7
As Lead Sponsor
2
As Collaborator
5
Total Enrollment
1,053
NCT00089700
TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2004
Completion: Not specified
NCT01438853
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Phase: Phase 1
Role: Collaborator
Start: Dec 31, 2004
Completion: Feb 29, 2008
NCT00264849
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Phase: Phase 4
Start: Nov 30, 2005
Completion: Sep 30, 2008
NCT00267202
Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
Start: Dec 31, 2005
Completion: Apr 30, 2008
NCT00441818
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma
Phase: Phase 1/2
Start: May 31, 2006
Completion: Jun 30, 2007
NCT00500539
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
Phase: Phase 3
Start: Jul 31, 2007
NCT00624832
A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
Start: Feb 29, 2008
Completion: Jan 31, 2009